GenScript ProBio, a US-based global Contract Development and Manufacturing Organisation (CDMO), announced on Wednesday that it has agreed to set up a strategic partnership with RVAC Medicines Pte. Ltd., a Singapore-based biotechnology company focusing on the development and commercialisation of messenger RNA (mRNA) therapeutics and vaccines.
The companies are partnering for the production of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with a collaboration for future therapeutic pipelines.
Under the partnership, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. This partnership is intended to enable RVAC Medicines to accelerate its clinical manufacturing of mRNA-based COVID-19 vaccine, RVM-V001, and future mRNA-based vaccines targeting infectious diseases such as Respiratory syncytial virus (RSV) and Clostriodioides difficile infection (CDI).
RVAC Medicines is to continue to partner with GenScript ProBio to support its mRNA initiatives for both clinical-stage development and commercial stage.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses